Charles Craddock

University of Birmingham

United Kingdom

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (18)

Collaborators (12)

Jesus Duque-Afonso

faculty of medicine university of freiburg freiburg germany

Roland B. Walter

University of Washington

UNITED STATES

Agnieszka Wierzbowska

Medical University of Lodz

Ravindra Majeti

Stanford University

UNITED STATES

Hayden Pearce

University of Birmingham

UNITED KINGDOM

Richard Larson

University of Chicago

UNITED STATES

Gerard Socie

Nicolaus Kröger

Bob Löwenberg

Paresh Vyas

University of Oxford

UNITED KINGDOM

Sylvie Freeman

University of Birmingham

UNITED KINGDOM

Justin Loke

University of Birmingham

UNITED KINGDOM

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Charles Craddock

Research Interests

Explore related searches

Contact this professor

Articles (18)

Collaborators (12)

Jesus Duque-Afonso

Roland B. Walter

Agnieszka Wierzbowska

Ravindra Majeti

Hayden Pearce

Richard Larson

Gerard Socie

Nicolaus Kröger

Bob Löwenberg

Paresh Vyas

Sylvie Freeman

Justin Loke

Make your next move.

Charles Craddock

Research Interests

Explore related searches

Contact this professor

Articles (18)

CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHD

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old

Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance

Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia

Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome

Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party

Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Reply to G. Gui et al

Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

Acute myeloid leukaemia therapeutic innovation and clinical trials: past, present and future

Bone marrow transplantation in the United Kingdom – past, present and future

Collaborators (12)

Jesus Duque-Afonso

Roland B. Walter

Agnieszka Wierzbowska

Ravindra Majeti

Hayden Pearce

Richard Larson

Gerard Socie

Nicolaus Kröger

Bob Löwenberg

Paresh Vyas

Sylvie Freeman

Justin Loke

Make your next move.